Farringdon Capital Ltd. Takes $373,000 Position in Cabot Co. (NYSE:CBT)

Farringdon Capital Ltd. bought a new stake in Cabot Co. (NYSE:CBT - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 4,089 shares of the specialty chemicals company's stock, valued at approximately $373,000.

A number of other large investors also recently modified their holdings of CBT. American Century Companies Inc. boosted its position in shares of Cabot by 8.5% during the 4th quarter. American Century Companies Inc. now owns 1,323,347 shares of the specialty chemicals company's stock valued at $120,835,000 after purchasing an additional 103,380 shares in the last quarter. Sei Investments Co. boosted its holdings in Cabot by 6.0% during the fourth quarter. Sei Investments Co. now owns 942,273 shares of the specialty chemicals company's stock worth $86,039,000 after buying an additional 53,090 shares in the last quarter. Invesco Ltd. grew its position in Cabot by 7.1% in the fourth quarter. Invesco Ltd. now owns 845,261 shares of the specialty chemicals company's stock worth $77,181,000 after buying an additional 55,905 shares during the last quarter. Copeland Capital Management LLC increased its holdings in shares of Cabot by 21.6% in the fourth quarter. Copeland Capital Management LLC now owns 761,372 shares of the specialty chemicals company's stock valued at $69,521,000 after buying an additional 135,119 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Cabot by 0.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 710,608 shares of the specialty chemicals company's stock valued at $64,886,000 after acquiring an additional 3,175 shares during the last quarter. 93.18% of the stock is owned by institutional investors and hedge funds.

Cabot Price Performance

Shares of NYSE CBT traded up $2.09 during midday trading on Tuesday, reaching $79.24. 484,267 shares of the company traded hands, compared to its average volume of 387,868. Cabot Co. has a 12 month low of $73.63 and a 12 month high of $117.46. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.29 and a current ratio of 2.00. The stock's 50-day simple moving average is $82.54 and its 200-day simple moving average is $94.46. The firm has a market cap of $4.30 billion, a PE ratio of 10.52, a PEG ratio of 0.74 and a beta of 1.04.

Cabot (NYSE:CBT - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. As a group, equities analysts anticipate that Cabot Co. will post 7.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CBT has been the topic of a number of research analyst reports. UBS Group lowered their price target on Cabot from $93.00 to $83.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Mizuho decreased their price target on shares of Cabot from $122.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. StockNews.com upgraded Cabot from a "hold" rating to a "buy" rating in a research report on Thursday, April 17th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Cabot from $105.00 to $85.00 and set an "underweight" rating on the stock in a research report on Friday, February 21st.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.